Samsung Medical Center
| République de Corée | Turquie | Espagne | |
| Immunothérapie avec Keytruda (Pembolizumab) | de $5,200 | de $3,300 | de $15,000 |
| Chimiothérapie pour le cancer du sein | de $19,200 | de $1,200 | de $3,500 |
| Chimiothérapie intrapéritonéale hyperthermique (HIPEC) | de $23,500 | de $22,500 | de $25,000 |
| Ablation de la vessie | de $18,500 | de $8,000 | de $25,000 |
| Thérapie à l'actinium-225 | - | de $22,955 | de $45,000 |
Bookimed ne rajoute pas de frais pour les traitements de Cancer de la vessie. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Cancer de la vessie et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Cancer de la vessie.
Chef du département d'urologie de Samsung – le Dr Choi Han Yong est spécialisé dans le traitement du cancer de la vessie au Samsung Medical Center.
Dr. Son Dong Wan, MD, PhD, is the Chief of Urology at Naeun Hospital. He specializes in urologic oncology, urinary incontinence, sexual dysfunction, and laser prostate surgery. He performs robotic and laparoscopic surgery for cancers of the prostate, bladder, ureter, and kidney. He also treats ureteropelvic junction (UPJ) obstruction.
He earned his PhD from Pusan National University. He completed his internship and residency at Pusan National University Hospital. He is a former Chief at Wallace Memorial Baptist Hospital. He served as a Professor at the Catholic University College of Medicine. He was a Clinical Fellow at Seoul National University Bundang Hospital. He was a Visiting Professor at the University of California, San Diego (UCSD). He completed training in urinary incontinence surgery at the University of Liège.
Awards include the Excellent Paper Award (2007) and the Academic Achievement Award (2014) from the Korean Continence Society. He also received the Best Poster Award from the European Association of Urology (2013).
Le Dr Won Sik Ham est spécialisé en urologie et en oncochirurgie à l'hôpital Severance.
Spécialiste en chirurgie laparoscopique et robotique du cancer de la vessie à l'hôpital Severance.
Robotic surgery is widely available for bladder cancer in South Korea. Leading medical centers in Seoul and Incheon utilize the da Vinci surgical system for complex oncology. These facilities maintain high standards with Joint Commission International and KOIHA accreditations for patient safety.
Bookimed Expert Insight: South Korea clinical volume provides a unique safety advantage for international patients. Severance Hospital alone treats over 4,000,000 patients annually and maintains a dedicated robotic surgery center. This massive scale allows surgeons like Dr. Koon Ho Rha to build experience levels that are rare even in Western tertiary centers. Patients should prioritize hospitals with over 30,000 annual operations to ensure they are treated by high-volume robotic teams.
South Korea offers systemic immunotherapies including Keytruda and Opdivo alongside cellular treatments like CAR-T and NK cell therapy. These protocols are available at JCI-accredited centers in Seoul. Specialists use these biologics for bladder, lung, and liver cancers to stimulate natural immune responses.
Bookimed Expert Insight: While many focus on drug costs, the real differentiator in Korea is digital integration. Centers like Seoul National University Bundang Hospital use the BESTcare system to sync genomic data with immunotherapy protocols. This reduces dosing errors and aligns treatment precisely with real-time patient blood markers.
Patient Consensus: Patients note the speed of starting treatment is impressive. Many emphasize that having a dedicated coordinator for translation makes navigating complex oncology schedules much easier.
Bladder replacement is a surgical procedure called neobladder reconstruction. While surgery is the primary curative approach for muscle-invasive cancer, non-surgical alternatives in Korea include drug-based immunotherapy with Keytruda. Other options include chemotherapy and Hyperthermic Intraperitoneal Chemotherapy to manage advanced cases without immediate removal.
Bookimed Expert Insight: Korea University Anam Hospital possesses notable expertise in Asian urological oncology and was among the first to perform robotic surgeries. Our data shows that while neobladder reconstruction is standard for invasive cases, centers like Samsung Medical Center utilize AI and advanced imaging to determine if bladder-sparing treatments are viable based on 2,000,000+ annual patient data points.
Patient Consensus: Patients note it is important to clarify if the treatment is curative or palliative. Many emphasize the relief of finding robotic options that prioritize faster recovery times.
Leading Korean hospitals for bladder cancer include Samsung Medical Center and Severance Hospital. These facilities specialize in robotic cystectomy and artificial bladder reconstruction. Many clinics hold JCI and KOIHA accreditations. They offer advanced therapies like HIPEC and immunotherapy to improve long-term survival for oncology patients.
Bookimed Expert Insight: Korea University Anam Hospital stands out for patients prioritizing technological firsts. While large centers like Samsung treat over 2,000,000 patients annually, Anam Hospital pioneered robotic bladder surgery in Asia. This concentration on robotic innovation often leads to more refined techniques for nerve-sparing and bloodless procedures.
International patients typically enter South Korea for bladder cancer treatment using the K-ETA electronic authorization or a standard C-3-9 medical visa. Short-term care under 90 days often requires only a tourist entry. Longer protocols like chemotherapy or immunotherapy may require a formal medical visa extension.
Bookimed Expert Insight: Korea University Anam Hospital performed Asia's first robotic bladder cancer surgery. Our data shows that while many patients enter on 90-day waivers, complex oncological cases often require transitioning to a C-3-M or G-1 medical visa. Major centers like Samsung Medical Center and Asan Medical Center maintain specialized teams to coordinate these legal transitions with the immigration office without interrupting your treatment schedule.
Patient Consensus: Patients note that standard tourist entries work well for initial consultations and diagnostics. For long-term chemotherapy, they emphasize getting a hospital invitation letter early to avoid visa extension delays.